论文部分内容阅读
目的:探讨血管紧张素受体拮抗剂(Ang RA)缬沙坦对糖尿病肾病患者血、尿内皮素水平的影响,以了解其临床意义。方法:将37例2型早期糖尿病肾病患者随机分为治疗组(19例)和非治疗组(18例)。3个月后检测两组患者血、尿内皮素水平。结果:缬沙坦治疗组血、尿内皮素比治疗前降低,差异有显著性(P<0.05);而非治疗组的血尿内皮素和治疗前比较无显著性差异(P<0.05)。结论:缬沙坦能降低糖尿病肾病患者血、尿内皮素水平,保护糖尿病肾病患者的肾脏。
Objective: To investigate the effect of valsartan, an angiotensin receptor blocker (Ang RA) antagonist, on the levels of blood and urine endothelin in patients with diabetic nephropathy. Methods: Thirty-seven patients with type 2 early diabetic nephropathy were randomly divided into treatment group (n = 19) and non-treatment group (n = 18). After 3 months, blood and urinary endothelin levels were measured in both groups. Results: The levels of blood and urine endothelin in the valsartan treatment group were significantly lower than those before treatment (P <0.05), while those in the non-treatment group were not significantly different from those before treatment (P <0.05). Conclusion: Valsartan can reduce the level of blood and urine endothelin in patients with diabetic nephropathy and protect the kidney of patients with diabetic nephropathy.